4D Molecular Therapeutics... (FDMT)
4D Molecular Therapeutics Statistics
Share Statistics
4D Molecular Therapeutics has 46.3M shares outstanding. The number of shares has increased by -10.45% in one year.
| Shares Outstanding | 46.3M |
| Shares Change (YoY) | -10.45% |
| Shares Change (QoQ) | 0.16% |
| Owned by Institutions (%) | 84.35% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 358 |
| FTD / Avg. Volume | 0.04% |
Short Selling Information
The latest short interest is 5.2M, so 11.25% of the outstanding shares have been sold short.
| Short Interest | 5.2M |
| Short % of Shares Out | 11.25% |
| Short % of Float | 11.71% |
| Short Ratio (days to cover) | 5.22 |
Valuation Ratios
The PE ratio is -1.87 and the forward PE ratio is -0.89. 4D Molecular Therapeutics's PEG ratio is -0.12.
| PE Ratio | -1.87 |
| Forward PE | -0.89 |
| PS Ratio | 8120.72 |
| Forward PS | 1.2 |
| PB Ratio | 0.59 |
| P/FCF Ratio | -2.23 |
| PEG Ratio | -0.12 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for 4D Molecular Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 14.92, with a Debt / Equity ratio of 0.05.
| Current Ratio | 14.92 |
| Quick Ratio | 14.92 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | -0.13 |
| Debt / FCF | -0.18 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $163 |
| Profits Per Employee | $-708,669.6 |
| Employee Count | 227 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -86.96% in the last 52 weeks. The beta is 2.88, so 4D Molecular Therapeutics's price volatility has been higher than the market average.
| Beta | 2.88 |
| 52-Week Price Change | -86.96% |
| 50-Day Moving Average | 3.62 |
| 200-Day Moving Average | 8.41 |
| Relative Strength Index (RSI) | 53.31 |
| Average Volume (20 Days) | 810,790 |
Income Statement
In the last 12 months, 4D Molecular Therapeutics had revenue of 37K and earned -160.87M in profits. Earnings per share was -2.98.
| Revenue | 37K |
| Gross Profit | 37K |
| Operating Income | -187.84M |
| Net Income | -160.87M |
| EBITDA | -187.84M |
| EBIT | -187.84M |
| Earnings Per Share (EPS) | -2.98 |
Balance Sheet
The company has 149.34M in cash and 24.61M in debt, giving a net cash position of 124.73M.
| Cash & Cash Equivalents | 149.34M |
| Total Debt | 24.61M |
| Net Cash | 124.73M |
| Retained Earnings | -576.2M |
| Total Assets | 560.38M |
| Working Capital | 405.78M |
Cash Flow
In the last 12 months, operating cash flow was -134.59M and capital expenditures 0, giving a free cash flow of -134.59M.
| Operating Cash Flow | -134.59M |
| Capital Expenditures | n/a |
| Free Cash Flow | -134.59M |
| FCF Per Share | -2.49 |
Margins
Gross margin is 100%, with operating and profit margins of -507678.38% and -434778.38%.
| Gross Margin | 100% |
| Operating Margin | -507678.38% |
| Pretax Margin | -434778.38% |
| Profit Margin | -434778.38% |
| EBITDA Margin | -507678.38% |
| EBIT Margin | -507678.38% |
| FCF Margin | -363743.24% |
Dividends & Yields
FDMT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for FDMT is $35.5, which is 932% higher than the current price. The consensus rating is "Buy".
| Price Target | $35.5 |
| Price Target Difference | 932% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
Scores
| Altman Z-Score | 0.19 |
| Piotroski F-Score | 2 |